A carregar...
Receptor tyrosine kinases in cancer escape from BRAF inhibitors
The BRAF inhibitors (BRAFi) induce anti-tumor responses in nearly 60% of patients with advanced (V600)BRAF-mutant melanomas but only 5% of patients with (V600)BRAF-mutant colorectal carcinomas. Earlier studies of how a subset of melanoma that initially responds to BRAFi but later acquires drug resis...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3367528/ https://ncbi.nlm.nih.gov/pubmed/22565288 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cr.2012.78 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|